Evidence map›Paper›PMID 32943729›Full record

ArticleOncogene2020

Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner.

Qingbo Huang, Yin Sun, Wei Zhai, Xin Ma, Donglai Shen, Songliang Du, Bosen You, Yuanjie Niu, Chi-Ping Huang, Xu Zhang and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. The influence of sex hormones on renal cell carcinoma.Therapeutic advances in medical oncology · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Qingbo Huang *Department of Urology, Chinese PLA General Hospital, 100853, Beijing, China.ORCID http://orcid.org/0000-0003-2894-0187
Yin Sun *George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Wei Zhai *George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, 14642, USA.ORCID http://orcid.org/0000-0001-6274-6404
Xin Ma *Department of Urology, Chinese PLA General Hospital, 100853, Beijing, China.
Donglai ShenDepartment of Urology, Chinese PLA General Hospital, 100853, Beijing, China.
Songliang DuDepartment of Urology, Chinese PLA General Hospital, 100853, Beijing, China.ORCID http://orcid.org/0000-0002-8156-0792
Bosen YouGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Yuanjie NiuGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Chi-Ping HuangSex Hormone Research Center, Department of Urology, China Medical University/Hospital, Taichung, 404, Taiwan.
Xu ZhangDepartment of Urology, Chinese PLA General Hospital, 100853, Beijing, China. xzhang@foxmail.com.ORCID http://orcid.org/0000-0002-6908-6768
Chawnshang ChangGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, 14642, USA. chang@urmc.rochester.edu.ORCID http://orcid.org/0000-0001-8510-3516
Chinese PLA General Hospital · CNUniversity of Rochester Medical Center · USChina Medical University · TWRenji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies indicated that the androgen receptor (AR) plays important roles in modulating metastasis of VHL-mutant clear cell renal cell carcinoma (ccRCC). However, the precise mechanisms of AR roles in VHL wild-type (VHL-wt) ccRCC, remain unclear. Here we found that AR interacted with VHL to modulate the metastasis of VHL-wt ccRCC via an oxygen-dependent manner. Mechanism dissection revealed that AR could transcriptionally suppress the miR-185-5p expression in the presence of functional VHL-wt protein under a normoxic condition, which might then result in increasing the expression of VEGF-A and VEGF-C via targeting the 3'UTR of mRNAs at a post-transcriptional level. In contrast, under a hypoxic condition, AR could increase miR-185-5p expression to suppress VEGF-C expression, yet this miR-185-5p effect on VEGF-A was reversed via AR's positive regulation on the HIF2α-increased VEGF-A expression that resulted in increasing VEGF-A in the VHL-wt RCC cells. These distinct AR functions under different oxygen conditions may involve the VHL-impacted ubiquitination and nuclear localization of AR. The differential regulation of VEGF-A vs VEGF-C by AR may then result in differential impacts on the ccRCC metastatic destinations of VHL-wt ccRCC cells under different oxygen conditions. These finer mechanisms may help in the development of a novel therapy to better suppress the ccRCC progression under different oxygenization conditions.

Indexed as

3' Untranslated RegionsAnimalsBasic Helix-Loop-Helix ProteinsCarcinoma, Renal CellCell HypoxiaCell Line, TumorEndothelial PAS Domain-Containing Protein 1Gene Knockdown TechniquesHumansKidney NeoplasmsMaleMiceMicroRNAsOxygenReceptors, AndrogenRNA Interference3' Untranslated RegionsAR protein, humanBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1MicroRNAsMIRN185 microRNA, humanOxygenReceptors, AndrogenVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CVEGFA protein, humanVEGFC protein, humanVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID32943729
OpenAlexW3087305934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.